Deferasirox
Deferasirox is a drug used to treat Iron Overload, Myelodysplastic Syndromes, Myelodysplastic Syndrome, and other conditions. Deferasirox is being actively studied in 2 studies and prior, has been studied in 39.
| Top Sponsors | Top Sites | Top Investigators |
|---|---|---|
| Novartis Pharmaceuticals | Novartis Investigative Site | Amit Pandya |
| Novartis | Children's Hospital Boston | Antonello Di Paolo, M.D., Ph.D. |
| Boston Children's Hospital | Children's Hospital of Philadelphia | Dr Koren Ariel |
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
U
Recruiting
- Myelodysplasia
- Deferasirox
- Grenoble, FranceCHU de GRENOBLE ALPES
2021-10-01
Oct 1, 2021N
Completed
- Beta-thalassemia
- Iron Overload
- Deferasirox
- Los Angeles, California
- +2 more
2021-06-08
Jun 8, 2021U
Active, not recruiting
- Iron Overload
- Deferasirox
- Trieste, ItalyIRCCS Burlo Garofolo
2022-01-04
Jan 4, 2022N
Completed
- Myelodysplastic Syndromes
- Iron Overload
- Deferasirox
- Stanford, California
- +2 more
2021-06-01
Jun 1, 2021N
Completed
- β-thalassemia
- Transfusional Iron Overload
- Deferasirox
- Cagliari, CA, Italy
- +2 more
2020-12-06
Dec 6, 2020N
Completed
- Hepatic Impairment
- Deferasirox
- Kiel, GermanyNovartis Investigative Site
2020-12-06
Dec 6, 2020F
Terminated
- Anemia
- Myelodysplastic Syndrome
- Deferasirox
- Laboratory Biomarker Analysis
- Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
2020-06-12
Jun 12, 2020N
Completed
- Iron Overload
- Deferasirox
- Zagazig, Egypt
- +9 more
2020-08-24
Aug 24, 2020C
S
Withdrawn
- Transfusional Iron Overload
- +6 more
- SPD602
- Deferasirox
- (no location specified)
2021-06-01
Jun 1, 2021N
Completed
- Chronic Iron Overload
- Deferasirox
- Vienna, Austria
- +13 more
2020-02-18
Feb 18, 2020N
Terminated
- Transfusion-dependent β-thalassemia Patients
- Cardiac Iron Overload
- Deferasirox
- Deferoxamine (DFO)
- Athens, GR, Greece
- +3 more
2019-10-21
Oct 21, 2019N
Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients - 2008
Completed
- Myelodysplastic Syndrome
- Iron Overload
- Deferasirox
- Birmingham, Alabama
- +47 more
2021-07-21
Jul 21, 2021N
Completed
- Non-transfusion Dependent Thalassemia
- deferasirox
- Nanning, Guangxi, China
- +10 more
2019-09-19
Sep 19, 2019B
Completed
- Transfusion-dependent Hemachromatosis
- +2 more
- Deferoxamine
- +2 more
- Boston, MassachusettsChildren's Hospital Boston
2019-06-14
Jun 14, 2019E
Terminated
- Acute Myeloid Leukemia
- Deferasirox
- +2 more
- Maywood, IllinoisLoyola University Cardinal Bernardin Cancer Center
2020-02-25
Feb 25, 2020F
Unknown status
- Myelodysplastic Syndromes
- Deferasirox
- Firenze, FI, Italy
- +9 more
2019-07-15
Jul 15, 2019N
Completed
- Myelodysplastic Syndromes
- Deferasirox
- Placebo
- Anaheim, California
- +71 more
2020-10-30
Oct 30, 2020N
Terminated
- Myelodysplastic Syndrome
- Bone marrow aspirate
- Deferasirox
- Liege, BelgiumNovartis Investigative Site
2018-07-24
Jul 24, 2018N
Completed
- Transfusion-dependent Iron Overload
- Deferasirox
- Adelaide, Australia
- +97 more
2020-02-08
Feb 8, 2020C
Terminated
- Iron Overload
- +101 more
- deferasirox
- Duarte, CaliforniaCity of Hope
2019-06-07
Jun 7, 2019M
Terminated
- Breast Cancer
- +7 more
- deferasirox
- Minneapolis, MinnesotaMasonic Cancer Center at University of Minnesota
2017-12-03
Dec 3, 2017W
Completed
- Acute Undifferentiated Leukemia
- +135 more
- deferasirox
- +2 more
- Winston-Salem, North CarolinaComprehensive Cancer Center of Wake Forest University
2018-08-07
Aug 7, 2018N
Completed
- Beta-thalassemia
- +4 more
- Deferasirox
- Oakland, California
- +5 more
2017-08-17
Aug 17, 2017N
Withdrawn
- Focus on Transfusion Dependent Thalassemia Patients Who Are Inadequate Responders to Deferasirox > 35mg/kgQD
- Deferasirox
- (no location specified)
2017-04-19
Apr 19, 2017